Ambrx Biopharma Inc. Increase (Decrease) in Accrued Liabilities
Ambrx Biopharma Inc. reported Increase (Decrease) in Accrued Liabilities of -$926.00 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2023-08-09
- Ambrx Biopharma Inc. increase (decrease) in accrued liabilities for the quarter ending 2023-06-30 was $3.08M, a 12.27% increase year-over-year.
- Ambrx Biopharma Inc. increase (decrease) in accrued liabilities for the quarter ending 2023-03-31 was -$4.01M.
- Ambrx Biopharma Inc. increase (decrease) in accrued liabilities for the quarter ending 2022-06-30 was $2.75M.
- Ambrx Biopharma Inc. increase (decrease) in accrued liabilities for the quarter ending 2022-03-31 was -$4.37M.
- Ambrx Biopharma Inc. increase (decrease) in accrued liabilities for fiscal 2022 was -$3.60M, a 134.33% decline from fiscal 2021.
- Ambrx Biopharma Inc. increase (decrease) in accrued liabilities for fiscal 2021 was $10.50M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|
| 2023-06-30 | $3.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$926.00K 10-Q · filed 2023-08-09 | |
| 2023-03-31 | -$4.01M 10-Q · filed 2023-05-11 | ||
| 2022-12-31 | -$3.60M 10-K · filed 2023-03-30 | ||
| 2022-06-30 | $2.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$1.62M 10-Q · filed 2023-08-09 | |
| 2022-03-31 | -$4.37M 10-Q · filed 2023-05-11 | ||
| 2021-12-31 | $10.50M 10-K · filed 2023-03-30 | ||
| 2021-06-30 | $4.29M 6-K · filed 2022-08-29 | ||
| 2020-12-31 | -$610.00K 20-F · filed 2022-04-26 | ||
| 2019-12-31 | $302.00K 20-F · filed 2022-04-26 |